
| 1. Svenonius E, et al. Allergy 1994; 49: 408–12 |
| |
Both Bricanyl Turbuhaler and Bricanyl pMDI* were effective in restoring lung function following exercise in children aged 9–17 years with chronic asthma.
Inhaled Bricanyl is effective in exercise-induced asthma in children

The bronchodilating effects of inhalation from Turbuhaler (0.5 mg terbutaline x 2) were compared with the effects of inhalation from a pressurized metered-dose inhaler (0.25 terbutaline x 4) in children with reproducible, exercise-induced asthma.
Adapted from Svenonius et al., 1994.
*No longer available |
| |
| 2. Lopes Dos Santos JM, et al. Allergy 1991; 46: 203–5 |
| |
Bricanyl Turbuhaler gave a significant increase in lung function following exercise-induced asthma in children aged 7–14 years, returning respiratory parameters to pre-challenge values. Similar effects were achieved with salbutamol administered via an alternative dry powder inhaler.
Bricanyl Turbuhaler is effective in exercise-induced asthma in children

Bricanyl Turbuhaler (0.5 mg terbutaline) and Ventolin Rotahaler (0.4 mg salbutamol) were compared in a randomized, double-blind, placebo-controlled study on exercise-induced asthma in 19 children.
Adapted from Lopes Dos Santos et al., 1991.
RotahalerTM is a registered trademark of Glaxo Smith Kline. |
| |
| 3. Pedersen S. In: Newman SP, et al Eds. A new concept in inhalation therapy. Proceedings of an international workshop on a new inhaler. Medicom; 21–22 May 1987: 146–50 |
| |
Bricanyl Turbuhaler 0.5 mg produced significantly greater improvement in exercise-induced bronchoconstriction in children aged 6–14 years than salbutamol 0.2 mg, administered via an alternative dry powder inhaler (Rotahaler) which had to be loaded.
Bricanyl Turbuhaler is effective for exercise challenge

In a double-blind crossover study, 17 children with bronchoconstriction after exercise received either placebo, 0.5 mg Bricanyl Turbuhaler, or 0.2 mg salbutamol via Rotahaler.
Adapted from Pedersen, 1987.
RotahalerTM is a registered trademark of Glaxo Smith Kline. |
| |
back to top
|
|